Skip to main content
. 2024 Oct 1;25:327. doi: 10.1186/s12882-024-03784-8

Table 2.

Treatment regimens during the follow-up

Treatment Patients with primary MN (n=558)
Cyclophosphamide and glucocorticoids, n (%) 221 (39.6)
Calcineurin inhibitors with or without glucocorticoids, n (%) 242 (43.4)
Glucocorticoid monotherapy, n (%) 144 (25.8)
Rituximab, n (%) 51 (9.1)
Mycophenolic acid analogs with or without glucocorticoids, n (%) 25 (4.5)
Azathioprine with or without glucocorticoids, n (%) 24 (4.3)